Novadip was founded in 2013 as spin-off comany from Université Catholique de Louvain and St. Luc University Hospital, based on the scientific discoveries of professor and founder Dr. Denis Dufrane. The creation of Novadip was supported by the Louvain Technology Transfer Office, Sopartec and VIVES II. 

Novadip's focus lies on two main products that focus on bone and tissue regeneration with a single treatment cure. NVD003 is their autologous cell-based product designed to regenerate bone deficits in large defects, with a lead indication for congenital pseudoarthritis of the tibia (CPT). NVDX3 is their 'off-the-shelf' allogenic bone graft designed to accelerate bone healing for patients at high risk of non-union. All Novadip's product candidates originate from their proprietary 3M³ platform that drives multiple classes of product candidates.